Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,252 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No label Clear all
Recruiting Early Phase 1 Interventional

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT07210632
View directory record Official record
Conditions
Brain Cancer, HGG, Glioma, High Grade Glioma, High Grade Gliomas, High Grade Glioma (III or IV), High Grade Glioma (HGG) of the Brain With BRAF Aberration
Interventions
Nivolumab, Nivolumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)

NCT03405792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, WHO Grade IV
Interventions
Temozolomide (TMZ), Optune System, Pembrolizumab
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

NCT02335944
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Capmatinib, Nazartinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 22, 2026, 2:04 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05421663
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Interventions
JNJ-90014496
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2041
U.S. locations
14
States / cities
Duarte, California • Denver, Colorado • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

NCT03224598
View directory record Official record
Conditions
Dermatosis Papulosa Nigra
Interventions
A-101 Topical Solution 40%
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 22, 2026, 2:04 AM EDT
Withdrawn Phase 1 Interventional

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

NCT04280471
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease, Severe Gastrointestinal Tract Acute Graft Versus Host Disease, Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease
Interventions
Fecal Microbiota Transplantation Capsule
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Not applicable Interventional

Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

NCT02200133
View directory record Official record
Conditions
Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT
Interventions
Individualized Survivorship Care Plan (SCP)
Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Scottsdale, Arizona • Gainesville, Florida • Maywood, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 22, 2026, 2:04 AM EDT
Not listed Phase 1 Interventional

Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy

NCT03672149
View directory record Official record
Conditions
Renal Replacement Therapy, Pharmacokinetics
Interventions
Cefazolin
Drug
Lead sponsor
Drexel University
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664
View directory record Official record
Conditions
Adult T-cell Leukemia-Lymphoma
Interventions
KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
Biological · Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 22, 2026, 2:04 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig (ABBV-383)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

NCT00955357
View directory record Official record
Conditions
Partial Epilepsies
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
17 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
40
States / cities
Irvine, California • Rancho Mirage, California • Clearwater, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 22, 2026, 2:04 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9 % sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

NCT02617758
View directory record Official record
Conditions
Healthy
Interventions
Fentanyl
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

NCT01183416
View directory record Official record
Conditions
Neuroblastoma
Interventions
3F8 monoclonal antibody and 13-cis-Retinoic Acid
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

NCT04447417
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 22, 2026, 2:04 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

NCT00688597
View directory record Official record
Conditions
Pompe Disease
Interventions
Duvoglustat
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 2:04 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

NCT03943615
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 22, 2026, 2:04 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

NCT07592689
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional

Study of INKmune in Patients With mCRPC (CaRe Prostate)

NCT06056791
View directory record Official record
Conditions
Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
Interventions
INKmune
Biological
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Las Vegas, Nevada • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

STAIR for Trauma and Emotion Dysregulation

NCT05397613
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Borderline Personality Disorder, Emotion Regulation
Interventions
STAIR
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Open Label Study: Treatment of ALS Fatigue With PolyMVA

NCT04557410
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PolyMVA
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

NCT01262118
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tasocitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
9
States / cities
Anniston, Alabama • Little Rock, Arkansas • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 22, 2026, 2:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Front-of-package Marketing on Fruit Drinks: Online RCT

NCT04811690
View directory record Official record
Conditions
Consumer Behavior, Consumer Preference
Interventions
front-of-package modification
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
5,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 22, 2026, 2:04 AM EDT